Back to Search
Start Over
Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs.
- Source :
-
PloS one [PLoS One] 2018 Nov 14; Vol. 13 (11), pp. e0206279. Date of Electronic Publication: 2018 Nov 14 (Print Publication: 2018). - Publication Year :
- 2018
-
Abstract
- Two chemotypes were examined in vitro with CYPs 3A4 and 2C19 by molecular docking, metabolic profiles, and intrinsic clearance deuterium isotope effects with specifically deuterated form to assess the potential for enhancement of pharmacokinetic parameters. The results show the complexity of deuteration as an approach for pharmacokinetic enhancement when CYP enzymes are involved in metabolic clearance. With CYP3A4 the rate limiting step was chemotype-dependent. With one chemotype no intrinsic clearance deuterium isotope effect was observed with any deuterated form, whereas with the other chemotype the rate limiting step was isotopically sensitive, and the magnitude of the intrinsic clearance isotope effect was dependent on the position(s) and extent of deuteration. Molecular docking and metabolic profiles aided in identifying sites for deuteration and predicted the possibility for metabolic switching. However, the potential for an isotope effect on the intrinsic clearance cannot be predicted and must be established by examining select deuterated versions of the chemotypes. The results show how in a deuteration strategy molecular docking, in-vitro metabolic profiles, and intrinsic clearance assessments with select deuterated versions of new chemical entities can be applied to determine the potential for pharmacokinetic enhancement in a discovery setting. They also help explain the substantial failures reported in the literature of deuterated versions of drugs to elicit a systemic enhancement on pharmacokinetic parameters.<br />Competing Interests: All authors were paid employees of Pfizer Inc at the time this work was done. Pfizer Inc provided all funding for this research. Some of the authors are owners of PFE stocks or shares and are named inventors on Pfizer patents. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Subjects :
- Cytochrome P-450 CYP2C19 radiation effects
Cytochrome P-450 CYP3A radiation effects
Deuterium pharmacology
Heme chemistry
Heme radiation effects
Humans
Inactivation, Metabolic
Kinetics
Microsomes radiation effects
Molecular Docking Simulation
Oxidation-Reduction radiation effects
Substrate Specificity
Cytochrome P-450 CYP2C19 chemistry
Cytochrome P-450 CYP3A chemistry
Deuterium chemistry
Pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 13
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 30427871
- Full Text :
- https://doi.org/10.1371/journal.pone.0206279